ADI-001 is a gene-modified cell therapy commercialized by Adicet Bio, with a leading Phase I program in B-Cell Non-Hodgkin Lymphoma. According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of ADI-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for ADI-001 is expected to reach an annual total of $171 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ADI-001 Overview

ADI-001 is under development for the treatment of non-Hodgkin’s lymphomas including follicular lymphoma, mantle-cell lymphoma, marginal zone lymphoma, mediastinal lymphoma, diffuse large b cell lymphoma. The therapeutic candidate comprises of allogenic gamma delta T cells expressing chimeric antigen receptors (CARs) directed to CD20. It acts by targeting cells expressing CD20. It is administered via parenteral route. The therapeutic candidate is being developed based on universal immune cell therapy (uICT) platform technology and T cell receptor-like monoclonal antibodies (TCRLs).

It was under development for the treatment of chronic lymphocytic leukemia (CLL), burkitt lymphoma.

Adicet Bio Overview

Adicet Bio, formerly resTORbio, is a biotechnology company. The company is engaged in developing allogeneic gamma delta T cell therapies for addressing the unmet medical need of solid tumors and hematological cancers. Adicet Bio’s pre-clinical pipeline includes ADI-001, a CD20 CAR-T cell therapy candidate for the treatment of non-hodgkin’s lymphoma; and ADI-002, a GPC3-targeting chimeric antigen receptor (CAR) for the treatment of hepatocellular carcinoma. It is also advancing the ADI-00x program for multiple solid tumors. Adicet Bio utilizes its proprietary immune cell platform that engineers gamma delta T cells with CARs and T cell receptors to generate T cell receptor-like monoclonal antibodies (TCRLs) directed to intracellular proteome to kill tumor cells. The company works in collaboration with Regeneron Pharmaceuticals Inc to develop engineered immune-cell therapeutics for cancer. It operates in the US. Adicet Bio is headquartered in Boston, Massachusetts, the US.

The company reported revenues of (US Dollars) US$9.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 45.7% over FY2020. The operating loss of the company was US$61.4 million in FY2021, compared to an operating loss of US$39.2 million in FY2020. The net loss of the company was US$62 million in FY2021, compared to a net loss of US$36.7 million in FY2020.

For a complete picture of ADI-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.